Publications by authors named "Daniel Verina"

Claim this Profile
P
Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma.
Ariel Siegel, Sidorela Reci, Leah Grossman, Charles Gleason, John Crary, Daniel Verina

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression of smoldering myeloma with treatment of Gaucher disease.
Kevin Barley, Anshuman Parekh, Syed Salam, Damodara Rao Mendu, Ravi Prakash Shukla, Daniel Verina

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Daniel Verina

J Hematol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Daniel Verina

J Hematol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Focus on Newly Diagnosed Multiple Myeloma.
Kevin Brigle, Daniel Verina, Beth Faiman

J Adv Pract Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Daniel Verina

Ther Adv Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Oliver Van Oekelen, Samir Parekh, Hearn J Cho, Nivetha Vishnuvardhan, Deepu Madduri, Daniel Verina

Leuk Lymphoma· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m.
Kevin Barley, Larysa Sanchez, Hearn J Cho, Samir Parekh, Deepu Madduri, Daniel Verina

Am J Hematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma
.
Kimberly Noonan, Sandra Rome, Beth Faiman, Daniel Verina

Clin J Oncol Nurs· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Young Adults with Multiple Myeloma.
Hollie Devine, Daniel Verina

Semin Oncol Nurs· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.
Ajai Chari, Hearn J Cho, Amishi Dhadwal, Gillian Morgan, Lisa La, Daniel Verina

Blood Adv· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis